MAPT and Alzheimer disease: To assess the prevalence of AD-tau co-pathology in FTLD-tau we performed immunohistochemical analysis with GT-38 to determine for the first time the AD-tau Braak stage in a cohort of 180 patients with neuropathologically confirmed FTLD-tau.